Skip to main content

Myriad Genetics' Tumor BRACAnalysis CDx Receives CE Mark

NEW YORK (GenomeWeb) – Myriad Genetics today announced that it has received CE marking in Europe for its Tumor BRACAnalysis CDx test. 

The test identifies tumors with mutations in the BRCA1 and BRCA2 genes. Myriad said that Tumor BRACAnalysis CDx is the only CE-marked tumor-based companion diagnostic test. It identifies patients who may benefit from AstraZeneca's Lynparza (olaparib), a poly ADP-ribose polymerase inhibitor. 

The European Medicines Agency and the US Food and Drug Administration approved Lynparza last month as a monotherapy for maintenance treatment of patients with platinum-sensitive relapsed BRCA-mutated high-grade serious epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. FDA also approved Myriad's test as a companion diagnostic for the drug. 

The test is offered throughout Europe by Myriad's subsidiary based in Zurich and is performed in the firm's Munich laboratories.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.